End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if CURE is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
3 top institutions tracked
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
20 filers reported a long position in CURE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| GOLDMAN SACHS GROUP INC | $4.6M | 41.2K | New |
| JANE STREET GROUP, LLC | $2.8M | 25.1K | +650.3% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.2M | 19.5K | +39% |
| SBI Securities Co., Ltd. | $559.4K | 5K | -21.5% |
| Traynor Capital Management, Inc. | $531.4K | 4.7K | -9.1% |
| Summit Financial, LLC | $460.4K | 4.1K | +44.1% |
| Larson Financial Group LLC | $319.4K | 2.8K | New |
| Onyx Bridge Wealth Group LLC | $279.6K | 2.5K | +0.3% |
| StoneX Group Inc. | $227.6K | 2.3K | New |
| Qube Research & Technologies Ltd | $136K | 1.2K | New |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.